Literature DB >> 6032481

Estimation of drug rejection by schizophrenic in-patients, with analysis of clinical factors.

J D Wilson, M D Enoch.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 6032481     DOI: 10.1192/bjp.113.495.209

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


× No keyword cloud information.
  7 in total

1.  Intranasal drug delivery of olanzapine-loaded chitosan nanoparticles.

Authors:  Sarah Baltzley; Atiquzzaman Mohammad; Ahmad H Malkawi; Abeer M Al-Ghananeem
Journal:  AAPS PharmSciTech       Date:  2014-08-21       Impact factor: 3.246

2.  Clozapine in the management of schizophrenia. Compliance no worse than with other neuroleptic drugs.

Authors:  J D Wilson
Journal:  BMJ       Date:  1993-07-17

3.  [Patient compliance (author's transl)].

Authors:  T Lüscher; H Vetter; P Greminger; R Steiner; W Siegenthaler; W Vetter
Journal:  Klin Wochenschr       Date:  1982-02-15

4.  Medication compliance among the seriously mentally ill in a public mental health system.

Authors:  C Nageotte; G Sullivan; N Duan; P L Camp
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1997-02       Impact factor: 4.328

5.  Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel.

Authors:  G Ginsberg; S Shani; B Lev
Journal:  Pharmacoeconomics       Date:  1998-02       Impact factor: 4.981

Review 6.  Patient compliance with drug therapy in schizophrenia. Economic and clinical issues.

Authors:  E Lindström; K Bingefors
Journal:  Pharmacoeconomics       Date:  2000-08       Impact factor: 4.981

7.  Fluphenazine decanoate in chronic schizophrenia.

Authors:  G D Shukla
Journal:  Indian J Psychiatry       Date:  1981-07       Impact factor: 1.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.